Sort   by:  
 Page size 
UnknownOne-Pot Terpolymerization of Macrolactones with Limonene Oxide and Phtalic Anhydride to Produce di-Block Semi-Aromatic Polyesters.
Not available
S-EPMC9695062 | biostudies-literature
UnknownActivity and Selectivity of Novel Chemical Metallic Complexes with Potential Anticancer Effects on Melanoma Cells.
Not available
S-EPMC10303371 | biostudies-literature
UnknownThe impact of gender bias in cardiothoracic surgery in Europe: a European Society of Thoracic Surgeons and European Association for Cardio-Thoracic Surgery survey.
Not available
S-EPMC9746891 | biostudies-literature
UnknownNon-IgE- or Mixed IgE/Non-IgE-Mediated Gastrointestinal Food Allergies in the First Years of Life: Old and New Tools for Diagnosis.
Not available
S-EPMC7829867 | biostudies-literature
UnknownThe Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study.
Not available
S-EPMC9563553 | biostudies-literature
UnknownCDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.
Not available
S-EPMC7830463 | biostudies-literature
UnknownPathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.
Not available
S-EPMC10335743 | biostudies-literature
UnknownAdjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Not available
S-EPMC10227592 | biostudies-literature
UnknownDistinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Not available
S-EPMC7027476 | biostudies-literature
UnknownComparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.
Not available
S-EPMC12152862 | biostudies-literature
Sort   by:  
 Page size